CJC-1295 (no DAC) + Ipamorelin Blend

CJC-1295 (no DAC) + Ipamorelin Blend — Research Use Only

The CJC-1295 (without DAC) + Ipamorelin peptide blend comprises two synthetic peptides utilized in biochemical and preclinical research to investigate modulation of growth hormone (GH) release pathways in pituitary cell cultures and animal model systems. CJC-1295 without DAC is a 29-amino acid modified analog of growth hormone-releasing hormone (GHRH) that activates GHRH receptors on somatotroph cells to drive pulsatile GH signaling with a short plasma half-life. Ipamorelin, a selective pentapeptide ghrelin mimetic, functions via the growth hormone secretagogue receptor (GHS-R1a) to stimulate acute GH exocytosis with high specificity and minimal impact on other pituitary axes in experimental assays. In research blends, the combination of GHRH receptor agonism from CJC-1295 without DAC with the complementary ghrelin pathway activation from Ipamorelin is studied for synergistic enhancement of GH secretion profiles, downstream IGF-1 signaling, and metabolic regulatory mechanisms in controlled laboratory models. These blends serve exclusively as investigational tools for exploring neuroendocrine peptide dynamics, receptor interactions, and cellular maintenance pathways in vitro and in vivo research settings. Not for use in any living organism.